Congo vs Fiji: Access to anti-retroviral drugs, male
Congo
40.0%
in 2024
Fiji
28.0%
in 2024
Congo rank
131st
Fiji rank
133rd
Access to anti-retroviral drugs, male over time
- Congo
- Fiji
How they compare
Congo currently reports 40.0% against 28.0% in Fiji, a difference of 12.0%.
That makes Congo's figure about 1.4 times Fiji's.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Fiji ahead.
Congo ranks 131st and Fiji ranks 133rd of 141 countries.
Across the 3 decades both report, Congo averaged higher in 1 and Fiji in 2.
Head to head by decade
| Decade | Congo | Fiji | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 4.9% | 41.2% | 36.3% | Fiji |
| 2010s | 20.4% | 33.5% | 13.1% | Fiji |
| 2020s | 31.8% | 19.6% | 12.2% | Congo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Congo or Fiji?
- Congo, at 40.0% against 28.0% in Fiji as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Congo and Fiji?
- 12.0%, with Congo ahead.
- How many years of comparable data are there for Congo and Fiji?
- 25 years are reported by both, from 2000 to 2024.
- How do Congo and Fiji rank globally for access to anti-retroviral drugs, male?
- Congo ranks 131st and Fiji ranks 133rd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.